Crohn Disease Treatment Algorithm - Flowchart
Crohn Disease Treatment Algorithm - Flowchart Crohn Disease Crohn Disease
«Flowchart»

Start

Start

Start

UGI disease

UGI disease

UGI disease UGI disease

Ileitis

Ileitis

Ileitis Ileitis

Ileocolitis/colitis

Ileocolitis/colitis

Ileocolitis/colitis Ileocolitis/colitis

Perianal disease

Perianal disease

Perianal disease Perianal disease

Fistulizing disease*

Fistulizing disease*

Fistulizing disease* * * Fistulizing disease


Mild to moderate
Extended release
Budesonide


Mild to moderate
Extended release
Budesonide


Mild to moderate
Extended release
Budesonide


Mild to moderate Mild to moderate
Extended release
Budesonide


Mild to moderate
Extended release
Budesonide


Mild to moderate
Extended release
Budesonide


Mild to moderate
Extended release
Budesonide


Mild to moderate Mild to moderate
Extended release
Budesonide


Mild to moderate
Immunomodulator
Anti–TNF- agents
Ustekinumab
Vedolizumab


Mild to moderate
Immunomodulator
Anti–TNF- agents
Ustekinumab
Vedolizumab


Mild to moderate
Immunomodulator
Anti–TNF- agents
Ustekinumab
Vedolizumab


Mild to moderate Mild to moderate
Immunomodulator
Anti–TNF- agents
Ustekinumab
Vedolizumab


Mild to moderate
Immunomodulator
Anti–TNF- agents
Antibiotics**


Mild to moderate
Immunomodulator
Anti–TNF- agents
Antibiotics**


Mild to moderate
Immunomodulator
Anti–TNF- agents
Antibiotics**


Mild to moderate Mild to moderate
Immunomodulator
Anti–TNF- agents
Antibiotics** ** **


Mild to moderate
Immunomodulator
Anti–TNF- agents
Antibiotics


Mild to moderate
Immunomodulator
Anti–TNF- agents
Antibiotics


Mild to moderate
Immunomodulator
Anti–TNF- agents
Antibiotics


Mild to moderate Mild to moderate
Immunomodulator
Anti–TNF- agents
Antibiotics

Moderate to severe


Corticosteroids induction
Immunomodulator: Anti–TNF- agents, vedolizumab, tofacitinib, natalizumab, ustekinumab
Supportive therapy for induction (NPO, TPN)

Moderate to severe


Corticosteroids induction
Immunomodulator: Anti–TNF- agents, vedolizumab, tofacitinib, natalizumab, ustekinumab
Supportive therapy for induction (NPO, TPN)

Moderate to severe

Moderate to severe


Corticosteroids induction
Immunomodulator: Anti–TNF- agents, vedolizumab, tofacitinib, natalizumab, ustekinumab
Supportive therapy for induction (NPO, TPN)


Corticosteroids induction
Immunomodulator: Anti–TNF- agents, vedolizumab, tofacitinib, natalizumab, ustekinumab
Supportive therapy for induction (NPO, TPN)

Refractory to medical therapy or perforation surgery

Refractory to medical therapy or perforation surgery

Refractory to medical therapy or perforation surgery

Refractory to medical therapy or perforation surgery

End

End

End

Moderate to severe


Temporary diversion surgery
Supportive therapy for
induction (NPO, TPN)

Moderate to severe


Temporary diversion surgery
Supportive therapy for
induction (NPO, TPN)

Moderate to severe

Moderate to severe


Temporary diversion surgery
Supportive therapy for
induction (NPO, TPN)


Temporary diversion surgery
Supportive therapy for
induction (NPO, TPN)

Persistent fistula


Temporary diversion surgery
Supportive therapy for induction (NPO, TPN)

Persistent fistula


Temporary diversion surgery
Supportive therapy for induction (NPO, TPN)

Persistent fistula

Persistent fistula


Temporary diversion surgery
Supportive therapy for induction (NPO, TPN)


Temporary diversion surgery
Supportive therapy for induction (NPO, TPN)

*Abscess should be excluded before initiating medical therapy

*Abscess should be excluded before initiating medical therapy

*Abscess should be excluded before initiating medical therapy

*

Proximal colon disease involvement.

Proximal colon disease involvement.

Proximal colon disease involvement.

**Perianal location.

**Perianal location.

**Perianal location.

**